Table 2.
Processes of Care Measured within a year after confirmatory eGFR for CKD among those with and without CKD recognition in the EHR problem list stratified by eGFR level
| Processes of care measures | eGFR 30–59 | eGFR <30 | ||
|---|---|---|---|---|
| No (N=22252) | Recognized (N=1934) | No (N=755) | Recognized (N=801) | |
| Nephrology Office visit, n (%) | 1010(4.5) | 681(35.2) | 147(19.5) | 456(56.9) |
| ACE/ARB, n Yes, (%) | 12796(57.5) | 1471(76.1) | 452(59.9) | 512(63.9) |
| Statin, n Yes, (%) | 12262(55.1) | 1257(65.0) | 390(51.7) | 475(59.3) |
| Metformin for diabetics, Yes, (%)[n=6476] | 818 (16.1) | 88 (11.2) | 7 (3.3) | <5 (0.3) |
| iPTH measured, n Yes, (%) | 1227(5.5) | 442(22.9) | 136(18.0) | 398(49.7) |
| Vitamin D measured n, Yes, (%) | 3920(17.6) | 424(21.9) | 95(12.6) | 203(25.3) |
| Phosphorus measured, n, Yes, (%) | 1618(7.3) | 561(29.0) | 189(25.0) | 450(56.2) |
| Any Proteinuria measured, n Yes (%) | 8035(36.1) | 1063(55.0) | 340(45.0) | 376(46.9) |
For patients with eGFR 30–59 all processes of care significantly different between patients with and without recognition, Chi-square p < 0.001. For patients with eGFR <30 nephrology visit, statin, iPTH, vitamin D, phosphorus and metformin for diabetics significantly different between patients with and without recognition, Chi-square p <0.05
eGFR = estimated glomerular filtration rate; CKD = chronic kidney disease; EHR = electronic health record; ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; iPTH = intact parathyroid hormone